Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy—Factors associated with advanced fibrosis

References

• Adam R, Karam V, Delvart V, O’Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012;57: 675–88.
   Google Scholar
• Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transplant 2003;9:S1–9.
   PubMed Web of Science ®Google Scholar
• Gibson A, Randall D, Degenhardt L. The increasing mortality burden of liver disease among opioid-dependent people: cohort study. Addiction 2011;106:2186–92.
   PubMedGoogle Scholar
• Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol 2013; 58:31–7.
   PubMed Web of Science ®Google Scholar
• Darke S, Kaye S, Duflou J. Systemic disease among cases of fatal opioid toxicity. Addiction 2006;101:1299–305.
   PubMed Web of Science ®Google Scholar
• John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol 2010;53:245–51.
   Google Scholar
• Kirk GD, Mehta SH, Astemborski J, Galai N, Washington J, Higgins Y, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013;158:658–66.
   PubMed Web of Science ®Google Scholar
• Copeland L, Budd J, Robertson JR, Elton RA. Changing patterns in causes of death in a cohort of injecting drug users, 1980–2001. Arch Intern Med 2004;164:1214–20.
   PubMedGoogle Scholar
• Fugelstad A, Annell A, Rajs J, Agren G. Mortality and causes and manner of death among drug addicts in Stockholm during the period 1981–1992. Acta Psychiatr Scand 1997; 96:169–75.
   PubMed Web of Science ®Google Scholar
• Larney S, Randall D, Gibson A, Degenhardt L. The contributions of viral hepatitis and alcohol to liver-related deaths in opioid-dependent people. Drug Alcohol Depend 2013; 131:252–7.
   Google Scholar
• Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O’Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008;103:462–8.
   PubMed Web of Science ®Google Scholar
• Gronbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 1990;82:223–7.
   PubMed Web of Science ®Google Scholar
• Gunne LM, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend 1981;7:249–56.
   PubMed Web of Science ®Google Scholar
• Larsson G. Bättre insatser vid missbruk och beroende, SOU 2011:35. Slutbetänkande Missbruksutredningen; 2011.
   Google Scholar
• Abdel-Hamid M, El-Daly M, Molnegren V, El-Kafrawy S, Abdel-Latif S, Esmat G, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 2007;88:1526–31.
   PubMed Web of Science ®Google Scholar
• Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005;43:250–7.
   PubMed Web of Science ®Google Scholar
• Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/ml by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology 2008;48:695.
   PubMed Web of Science ®Google Scholar
• Cross TJ, Calvaruso V, Maimone S, Carey I, Chang TP, Pleguezuelo M, et al. Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat 2010; 17:546–54.
   Google Scholar
• Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005;40:867–72.
   PubMed Web of Science ®Google Scholar
• Westin J, Ydreborg M, Islam S, Alsio A, Dhillon AP, Pawlotsky JM, et al. A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. Scand J Gastroenterol 2008;43:73–80.
   PubMed Web of Science ®Google Scholar
• Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343–50.
   PubMed Web of Science ®Google Scholar
• Krook AL, Stokka D, Heger B, Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res 2007;13:216–21.
   PubMed Web of Science ®Google Scholar
• Grebely J, Bryant J, Hull P, Hopwood M, Lavis Y, Dore GJ, et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011;18:e104–16.
   PubMed Web of Science ®Google Scholar
• Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102:1454–62.
   PubMed Web of Science ®Google Scholar
• Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013;158:807–20.
   PubMed Web of Science ®Google Scholar
• Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002;97:2408–14.
   PubMed Web of Science ®Google Scholar
• Patel A, Harrison SA. Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterol Hepatol 2012; 8:305–12.
   Google Scholar
• Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42:63–71.
   PubMed Web of Science ®Google Scholar
• Hezode C, Lonjon I, Roudot-Thoraval F, Mavier JP, Pawlotsky JM, Zafrani ES, et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003; 52:126–9.
   PubMed Web of Science ®Google Scholar
• Mohsen AH. The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 2001;48:707–13.
   PubMed Web of Science ®Google Scholar
• Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005;3:1150–9.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Kahan M, Ross S. The effect of methadone maintenance treatment on alcohol consumption: a systematic review. J Subst Abuse Treat 2008;34:215–23.
   PubMed Web of Science ®Google Scholar
• Hartzler B, Donovan DM, Huang Z. Comparison of opiate-primary treatment seekers with and without alcohol use disorder. J Subst Abuse Treat 2010;39:114–23.
   PubMed Web of Science ®Google Scholar
• Mysels DJ, Sullivan MA. The relationship between opioid and sugar intake: review of evidence and clinical applications. J Opioid Manag 2010;6:445–52.
   PubMedGoogle Scholar
• Rajs J, Petersson A, Thiblin I, Olsson-Mortlock C, Fredriksson A, Eksborg S. Nutritional status of deceased illicit drug addicts in Stockholm, Sweden—a longitudinal medicolegal study. J Forensic Sci 2004;49:320–9.
   PubMed Web of Science ®Google Scholar
• Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol 2013;59:696–700.
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30: 1054–8.
   PubMed Web of Science ®Google Scholar
• Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1–5.
   PubMed Web of Science ®Google Scholar
• Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614–8.
   PubMed Web of Science ®Google Scholar